Tempus and Daiichi Sankyo Partner on AI-Guided Cancer Biomarker Discovery

Tempus and Daiichi Sankyo have entered a collaboration to apply multimodal AI models and real-world clinical data to an oncology antibody-drug conjugate (ADC) program. The effort centers on improving patient selection and identifying biomarkers that can differentiate treatment response, aiming to increase clinical trial success rates and refine trial design.